Preclinical News and Research

RSS

Over twenty new drug metabolism assays launched by Absorption Systems

Absorption Systems, a leader in drug safety and ADMET (absorption, distribution, metabolism, excretion and toxicity) testing, today announced the introduction of a more complete series of drug metabolism assays designed to support the pharmaceutical R&D process, from early-stage discovery through late-stage clinical development.

2 Dec 2009

FDA approves revised clinical trial protocol for CytRx' arimoclomol

CytRx Corporation, a biopharmaceutical company, is permitted to re-enter the clinic with its orally administered molecular chaperone drug candidate arimoclomol as a therapeutic treatment for amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease), following the U.S. Food and Drug Administration’s (FDA) acceptance of a revised clinical trial protocol.

2 Dec 2009

Bioactive sponge to eliminate normally fatal tumors

InCytu Incorporated, a therapeutic device engineering company, announced the details of its Cellarium™ Cancer Vaccine program. Cellarium™ is a small bioactive sponge which regulates dendritic cells and T-cells to eliminate normally fatal tumors in a preclinical model of late stage melanoma. The details of such a promising new vaccine were published for the first time in Science’s Translational Medicine Journal.

2 Dec 2009

New data on pixantrone Phase III trial in non-Hodgkin's lymphoma to be presented

Cell Therapeutics, Inc. (CTI) announced today that Ruth Pettengell, M.D. of St. George's Hospital, University of London, the lead investigator for the PIX 301 EXTEND trial will present new data on the pixantrone phase III trial in relapsed/refractory aggressive non-Hodgkin's lymphoma (NHL) at the 51st Annual Meeting of the American Society of Hematology on Saturday, December 5, 2009 in New Orleans, Louisiana.

2 Dec 2009

MicroDose Therapeutx acquires a portfolio of compounds from Epix Pharmaceuticals

MicroDose Therapeutx Inc. today announced that it has acquired a portfolio of compounds for the potential treatment of chronic constipation, irritable bowel syndrome with constipation (IBS-C) and other diseases, from Epix Pharmaceuticals, Inc. (EPIX) (Lexington, MA).

2 Dec 2009

Acceleron Pharma announces study results of its ACE-011 and ACE-536 blood forming agents

Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, muscle, fat, and the vasculature, today announced that results from preclinical and clinical studies of two, novel blood forming agents, ACE-011 and ACE-536, will be presented at the 51st Annual Meeting of the American Society of Hematology at the Ernest N. Morial Convention Center in New Orleans, Louisiana.

1 Dec 2009

Calistoga Pharmaceuticals to present data on its CAL-101 inhibitor at the 51st ASH meeting

Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced that clinical and preclinical data supporting the role of CAL-101, an oral, p110δ(delta) selective PI3K inhibitor in patients with hematologic malignancies, will be featured in two oral presentations at the upcoming 51st American Society of Hematology (ASH) Annual Meeting taking place in New Orleans, LA.

1 Dec 2009

MedImmune to develop and commercialize Trellis Bioscience's anti-RSV antibodies

Trellis Bioscience, Inc. announced today the granting of a worldwide exclusive license to MedImmune, LLC, the global biologics unit of AstraZeneca, to develop and commercialize Trellis’ antibodies directed against the respiratory syncytial virus (RSV).

1 Dec 2009

Bioequivalence and comparable toxicity of ADVENTRX Pharmaceuticals' ANX-514 and Taxotere affirmed

ADVENTRX Pharmaceuticals, Inc. today announced that a new, recently completed preclinical study has affirmed the bioequivalence and comparable toxicity of ANX-514 and Taxotere® (docetaxel). Shin Poong Pharmaceuticals, ADVENTRX's partner for ANX-514 in South Korea, independently conducted the study and data analysis.

1 Dec 2009

StemCyte concludes exclusive license and commercialization agreement with Academia Sinica

StemCyte, Inc. concluded an exclusive license and commercialization agreement with Academia Sinica, the National Laboratory of Taiwan, for certain proprietary methods and Intellectual Property (IP) related to the treatment of Chronic Stroke with stem cells.

1 Dec 2009

Bayer Schering Pharma to develop new BiTE antibody for treatment of solid tumors

Micromet, Inc., a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases today announced that Bayer Schering Pharma AG has exercised its option under the option, collaboration and license agreement entered into on January 12, 2009 to develop a new BiTE antibody for the treatment of solid tumors.

1 Dec 2009

Akonni Biosystems receives $3.2M Phase II SBIR grant from NIH

Akonni Biosystems, a molecular diagnostics (MDx) company focused on providing rapid and highly scalable solutions for infectious disease testing, today announced receipt of a $3.2M Phase II SBIR grant from the National Institutes of Health (NIH).

1 Dec 2009

Completion of Phase I study of CPSI-2364 announced by Cytokine PharmaSciences

Cytokine PharmaSciences, Inc. today announced the completion of a Phase I study of CPSI-2364, its orally active, small-molecule inhibitor of the production of TNF-alpha and other pro-inflammatory cytokines.

1 Dec 2009

Cell Therapeutics' platinum-based anti-tumor compounds demonstrate stronger anti-tumor potency

Cell Therapeutics, Inc. (CTI) announced today that its new class of platinum-based anti-tumor compounds, termed bis-platinates, demonstrated a stronger anti-tumor potency and activity compared to currently available platinum-based compounds as well as the ability to overcome cisplatin-resistance in cancer cell lines.

30 Nov 2009

Rights Issue to be carried out by keeping the authorization by the Annual General Meeting, resolves Tripep

The Board of Directors of Tripep AB (publhas on the 27th of November 2009, based on the authorization by the Annual General Meeting resolved to carry out a rights issue.

27 Nov 2009

Tripep completes clinical trial of ChronVac-C for Hepatitis C virus treatment

All samples from the 12 patients with chronic Hepatitis C genotype 1 treated with Tripep’s therapeutic vaccine ChronVac-C have now been collected. The treatment was found to be safe, immunogenic and had transient effects on the serum levels of hepatitis C virus.

27 Nov 2009

OSEO awards fund for Galapagos NV's antibody therapeutics program

Galapagos NV announces that its antibody therapeutics program with MorphoSys and SARM program have been awarded funding by the French governmental organization OSEO.

26 Nov 2009

Merck to commence MK-6913 phase IIa efficacy trial for treatment of hot flashes/hot flushes

The Swedish biotech company Karo Bio today announced that Merck & Co., Inc., through an affiliate, plans to enter a clinical phase IIa trial with the collaboration's lead investigational drug candidate, MK-6913, identified as part of their joint research collaboration. No milestone payment to Karo Bio is associated with the initiation of phase II clinical development.

26 Nov 2009

CHMP positive opinion for marketing ELONVA in Europe

PROLOR Biotech, Inc., today noted the positive opinion by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency for marketing approval in Europe for ELONVA(R), a long-acting CTP-modified version of the fertility hormone FSH from Merck & Co. Merck and PROLOR are both licensees of the CTP technology from Washington University in St. Louis.

25 Nov 2009

Third-quarter financial results announced by SemBioSys Genetics

SemBioSys Genetics Inc., specializing in the manufacture of high-value proteins and oils in plant seeds, today announced its third quarter 2009 financial and operational results.

25 Nov 2009

Preclinical News and Research

Over twenty new drug metabolism assays launched by Absorption Systems

FDA approves revised clinical trial protocol for CytRx' arimoclomol

Bioactive sponge to eliminate normally fatal tumors

New data on pixantrone Phase III trial in non-Hodgkin's lymphoma to be presented

MicroDose Therapeutx acquires a portfolio of compounds from Epix Pharmaceuticals

Acceleron Pharma announces study results of its ACE-011 and ACE-536 blood forming agents

Calistoga Pharmaceuticals to present data on its CAL-101 inhibitor at the 51st ASH meeting

MedImmune to develop and commercialize Trellis Bioscience's anti-RSV antibodies

Bioequivalence and comparable toxicity of ADVENTRX Pharmaceuticals' ANX-514 and Taxotere affirmed

StemCyte concludes exclusive license and commercialization agreement with Academia Sinica

Bayer Schering Pharma to develop new BiTE antibody for treatment of solid tumors

Akonni Biosystems receives $3.2M Phase II SBIR grant from NIH

Completion of Phase I study of CPSI-2364 announced by Cytokine PharmaSciences

Cell Therapeutics' platinum-based anti-tumor compounds demonstrate stronger anti-tumor potency

Rights Issue to be carried out by keeping the authorization by the Annual General Meeting, resolves Tripep

Tripep completes clinical trial of ChronVac-C for Hepatitis C virus treatment

OSEO awards fund for Galapagos NV's antibody therapeutics program

Merck to commence MK-6913 phase IIa efficacy trial for treatment of hot flashes/hot flushes

CHMP positive opinion for marketing ELONVA in Europe

Third-quarter financial results announced by SemBioSys Genetics

Event guide: 4th LNP Formulation & Process Development Summit eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics